Figure 3.

Combo treatment can activate tumor-infiltrated T lymphocytes

Ratio of different T cell phenotypes and T cell-related functional analyses in CT26 murine colon TME by FACS. (A) Ratio of CD3⁺ in CD45⁺ cells (n = 5 for each group, one-way ANOVA, ∗p < 0.05). (B) Ratio of CD8⁺ in CD3⁺ T cells (n = 5 for each group, ∗p < 0.05. ∗∗p < 0.01, ∗∗∗∗p < 0.0001). (C) Representative pictures of CD8 IHC staining in TME and the quantification of the H-score of IHC staining for CD8 in CT26 murine colon tumor samples (scale bar, 50 μm; n = 3 for each group, ∗p < 0.05). (D) Quantification of IFN-γ⁺ CD8⁺ T cells and representative FACS histograms (n = 5 for each group, ∗p < 0.05, ∗∗p < 0.01). (E) Quantification of TNF-α⁺ CD4⁺ T cells, granzyme B⁺ CD8⁺ T cells, and Ki67⁺ CD4⁺ T cells (n = 5 for each group, ∗p < 0.05, ∗∗p < 0.01). (F) Quantification of IFN-γ⁺ CD4⁺ T cells and representative FACS histograms (n = 5 for each group, ∗p < 0.05, ∗∗p < 0.01). (G) Ratio of TNF-α⁺ CD4⁺ T cell, granzyme B⁺ CD4⁺ T cell, Ki67⁺ CD4⁺ T cell, and Th1/Treg (n = 5 for each group, ∗p < 0.05, ∗∗p < 0.01). Data are presented as mean ± SEM and analyzed by one-way ANOVA.